Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Östör A, Ng KJ, Gerwien J, Zaremba-Pechmann L, Brnabic AJM, Fautrel B

Open source

DOI
10.1007/s40744-025-00799-x
Published
2026 Feb
Container
Rheumatology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40744-025-00799-x,
  title = {Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.},
  author = {Alten R and Burmester GR and Matucci-Cerinic M and Salmon JH and Östör A and Ng KJ and Gerwien J and Zaremba-Pechmann L and Brnabic AJM and Fautrel B},
  year = {2026},
  journal = {Rheumatology and therapy},
  doi = {10.1007/s40744-025-00799-x},
  url = {https://doi.org/10.1007/s40744-025-00799-x}
}

RIS

TY  - JOUR
TI  - Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
AU  - Alten R
AU  - Burmester GR
AU  - Matucci-Cerinic M
AU  - Salmon JH
AU  - Östör A
AU  - Ng KJ
AU  - Gerwien J
AU  - Zaremba-Pechmann L
AU  - Brnabic AJM
AU  - Fautrel B
PY  - 2026
JO  - Rheumatology and therapy
DO  - 10.1007/s40744-025-00799-x
UR  - https://doi.org/10.1007/s40744-025-00799-x
ER  - 

APA

R, A., GR, B., M, M., JH, S., A, Ö., KJ, N., J, G., L, Z., AJM, B., & B, F. (2026). Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.. Rheumatology and therapy. https://doi.org/10.1007/s40744-025-00799-x

Source records